Jump to content



Recommended Posts


* Sonic Healthcare Ltd. <SHL.AX> rose 1.4 percent to A$14.76

after analysts upgraded their ratings and price targets on the

medical diagnostics firm following its purchase of Swiss

laboratory business Medica Laboratory Group for 98 million Swiss

francs ($80 million).

Credit Suisse upgraded Sonic to outperform from neutral while

lifting its price target to A$16.55 from A$16.05.

Link to comment
Share on other sites

  • 2 months later...
  • Replies 72
  • Created
  • Last Reply

Top Posters In This Topic

From Egoli site-


Sonic Healthcare books 15% rise in FY net profit


23/08/2007 By: Nicholas Grove


Sonic Healthcare Limited (SHL) has announced a 15% year-on-year increase in net profit for the 2007 financial year to $198.1 million. The medical diagnostics firm said the result was achieved on the back of $1,886.1 million in revenue, up 14% on the previous year.


As a result of acquisitions in 2007 and those announced after year-end, in addition to ongoing organic growth, Sonic said its revenue for 2008 is expected to be 20-25% above the 2007 figure.


The company expects earnings per share growth to be at least 12%, depending on foreign exchange and interest rate movements, the timing of settlement of announced acquisitions and the outcome of capital raisings announced today.


According to a newswire report, Sonic is planning to raise about $400 million through an institutional share placement by selling new shares in the $13.80-$14.50 rangey.


SonicÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s chief executive and managing director, Dr Colin Goldschmidt, said the companyÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s earnings exceeded guidance provided in August 2006.


ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Our core pathology companies have performed with distinction and are well placed to lead the groupÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s successes into the future,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ he said in a statement.


ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Our activities over recent months have seen SonicÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s growth accelerate substantially, with the acquisition of outstanding laboratory companies in Switzerland, Germany and the United States.


Dr Goldschmidt said with revenues set to increase to well over $2 billion in the 2008 financial year, Sonic is now the largest international diagnostic services company in the world.


ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Our plan for the future is to expand further in our three major markets of Australia, Europe and the USA,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ he added.


Dr Goldschmidt said Sonic is continuing negotiations with a number of acquisition and outsourcing targets in both the US and Europe.


He said he expects further significant growth in these large laboratory markets over the coming years.


Sonic declared a fully franked dividend of 29c per share, bringing total dividends for fiscal 2007 to 46c per share, up 12% on the previous year.


Sonic shares were placed on a trading halt this morning pending an announcement.


Link to comment
Share on other sites

  • 1 month later...
  • 2 months later...
  • 2 months later...
WELL with a good interim report out yesterday profit up 28% & div up 20% t0 20 cents what more could you want, But wait it was hit by a short sell off the latest weapon of hedge funds but it allows the small fry to get into the game bought a small parcel below $14 and finished the day @ $14.30.. This is a top company and has the market cornered in Blood testing and Ray treatment around the world, YES that's right "THE WORLD" not just like Dr Bateman`s SYB and in big debt SHL has very little debt and looking to EXPAND.. http://www.sharescene.com/html/emoticons/king.gif
Link to comment
Share on other sites

In reply to: theking on Wednesday 27/02/08 06:27am



Could not agree more.


SHL below $14 - a steal. Better than money in bank.


Yes SHL has been on spending / accumulation spree BUT these eggs will hatch. I would expect the next quarterly to be exceptional - outgoings done.


Only thorn for SHL is NZ fiasco. Once that is nailed, there anit no looking back.


This is a mid $20s stock. Be patient.



Link to comment
Share on other sites

  • 3 months later...

In reply to: Gum Nut on Wednesday 27/02/08 07:00am

Hi all,

Anyone knows what is going on with SHL? It has been hovering around the $14 for a long time now after highs of $17-18. I thought this one would follow the rest of the market back up, but that doesn't seem to be the case?

They are in the middle of some big acquisitions, but the news of these doesn't seem to have influenced the SP at all?

Any ideas?



Link to comment
Share on other sites

  • 4 months later...
  • 2 weeks later...
  • 2 months later...

Starting to go up in symapthy with CSL. Vol up slightly yest & following suit today.

Looks like funds are revolving to the defensive health sector again.

Back in again. Only looking for a move to first resis around 14.50 initially.


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...